NEW YORK (TheStreet) -- TheStreet's Debra Borchardt is with Francis Gaskins, Director of Research for Equities.com, discussing the three biotech IPOs this week. BlueBirdBio has a $75 million offering and just completed a deal with Celgene, which bode

Celgene International Sàrl (NASDAQ: CELG) was today notified that theEuropean Commission (EC) has amended the marketing authorisation forREVLIMID®.

The biopharma has bought back some $6.5 billion worth of stock over last four years.

SUMMIT, NJ (TheStreet) -- Celgene'sstrong stock performance this year started with the release of bullish, long-term (2017) guidance in early January. While Street estimates are generally close to Celgene's own forecasts, the biggest difference is wi

June 11 (Reuters) - Celgene Corp's experimental drug for psoriatic arthritis maintained its ability to significantly reduce painful symptoms through 52 weeks of treatment, according to data from a late stage study being presented this week at a medic

June 11 (Reuters) - Celgene Corp's experimental drug for psoriatic arthritis maintained its ability to significantly reduce painful symptoms through 52 weeks of treatment, according to data from a late stage study being presented this week at a medic

June 11 (Reuters) - Celgene Corp's experimentaldrug for psoriatic arthritis maintained its ability tosignificantly reduce painful symptoms through 52 weeks oftreatment, according to data from a...

By Peter Geschek:Celgene's (CELG) stated goal is to double its sales by 2017 and in order to achieve that, it pursues a three-way strategy: expand Revlimid, its core product, into new indications; develop new blockbusters and build its early stage pi

ByAbba's Aces:Since the beginning of the year all biotech and pharma companies have been making excellent gains, however, the biotech companies such as Celgene (CELG), Gilead (GILD), Biogen Idec (BIIB), and Regeneron (REGN) have been faltering of lat

Celgene Corporation (NASDAQ: CELG) today announced the U.S.

June 5 (Reuters) - Celgene Corp said on Wednesday that its flagship blood cancer drug, Revlimid, was approved by U.S. health regulators to treat mantle cell lymphoma, adding another revenue source for the $4 billion-a-year medicine.

June 5 (Reuters) - Celgene Corp said on Wednesdaythat its flagship blood cancer drug, Revlimid, was approved byU.S. health regulators to treat mantle cell lymphoma, addinganother revenue source...

June 5 (Reuters) - Celgene Corp said on Wednesday that its flagship blood cancer drug, Revlimid, was approved by U.S. health regulators to treat mantle cell lymphoma, adding another revenue source for the $4 billion-a-year medicine.

June 5 (Reuters) - Celgene Corp said on Wednesday that its flagship blood cancer drug, Revlimid, was approved by U.S. health regulators to treat mantle cell lymphoma, adding another revenue source for the $4 billion-a-year medicine.

June 5 (Reuters) - Celgene Corp said on Wednesday that its flagship blood cancer drug, Revlimid, was approved by U.S. health regulators to treat mantle cell lymphoma, adding another revenue source for the $4 billion-a-year medicine.

By A John Hodge:Celgene Stock Still Has Plenty of Room to Grow Due to a Strong Product LineThe global biopharmaceutical company, Celgene (CELG), has had quite a run this year; and judging by its sales and pipeline of products, the stock should contin

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation(NASDAQ: CELG), today announced data from a study comparing melphalan,prednisone and REVLIMID (lenalidomide) (MPR) with high-dose chemotherapy andtandem autologous stem cell

By James Burke:At the 2012, J.P. Morgan Health Care Conference, Celgene's (CELG) CEO Bob Hugins heralded the company's psoriatic compound as a potential blockbuster that appeared destined to become a primary drug in the psoriatic area of dermatology

LONDON, May 31 (Reuters) - European regulators have recommended approval of a new drug from Celgene for patients with multiple myeloma whose disease has worsened after being treated with other cancer drugs.

LONDON, May 31 (Reuters) - European regulators have recommended approval of a new drug from Celgene for patients with multiple myeloma whose disease has worsened after being treated with other cancer drugs.

Start Time: 09:00 End Time: 09:46 Celgene Corporation (CELG) Company Conference Presentation May 30, 2013, 09:00 AM ET Executives Jacqualyn A. Fouse - EVP and CFO Analysts Geoffrey Porges - Sanford C. Bernstein & Co. Presentation Geoffrey Porges - Sa

Having heard about and invested enough in large-cap pharma, I believe it is time to consider funding smaller firms in the sector. Below you will find three interesting mid and small-cap pharmaceutical companies, Celgene (Nasdaq: CELG), Alexion (Nasda

Investors in Celgene Corp. (NASD: CELG) saw new options become available today, for the June 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CELG options chain for the new June 7th contracts and identified

Investors eyeing a purchase of Celgene Corp. (NASD: CELG) shares, but cautious about paying the going market price of $125.30/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put c

Celgene's abraxane has recieved a priority review from the Food and Drug Administration.

Celgene International Sàrl, a subsidiary of Celgene Corporation (Celgene)(NASDAQ: CELG) today announced that the U.S.

Celgene Corporation (CELG)2013 UBS Global Healthcare Conference CallMay 22, 2013, 11:30 am ETExecutivesPerry Karsen - EVP & COOAnalystsMatt Roden - UBSPresentationMatt Roden - UBSHi good morning everybody. We are going to move on to the next company

Celgene (CELG) reported data from its ongoing Phase III trial of apremilast this month showing the drug successfully reduced psoriatic arthritis symptoms by at least 20% versus placebo.The data is good news for the 1 million diagnosed patients in the

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the latter two weeks of April.The number of shares sold short in Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ:

Editor's Note: This article was originally published on Real Money at 12:52 p.m. EDT on May 10. To see Jim Cramer's latest commentary as it's published, sign up for a free trial of Real Money. NEW YORK (Real Money) -- So, Celgene, Regeneron , Biogen

Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG)today announced that statistical significance was achieved for the primaryendpoint of ACR 20 at week 16 for patients receiving apremilast 20 mg and 30mg BID monotherapy in

Concert Pharmaceuticals, Inc. today announced that it has entered into astrategic collaboration with Celgene Corporation (NASDAQ: CELG) directed towardsdeuterium-modified compounds targeting cancer and inflammation.

FORMA Therapeutics Holdings, LLC (FORMA) today announced a strategiccollaboration agreement with Celgene Corporation (NASDAQ: CELG) under which FORMA and Celgenewill discover, develop and commercialize drug candidates to regulate proteinhomeostasis t

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the first two weeks of April.The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ:

Celgene Corporation (CELG)Q1 2013 Results Earnings CallApril 25, 2013 10:00 AM ETExecutivesPatrick Flanigan - Vice President, Investor RelationsBob Hugin - Chairman and CEOJackie Fouse - Chief Financial OfficerMark Alles - Global Head, Hematology and

By Albert Podell:I have been continuously long Celgene (CELG) for 18 years, have taken its pulse frequently during that period, and can speak to its outstanding health. I bought it at 70 cents (on a split-adjusted basis) and have held it through thic

Clean earnings reports from Biogen and Alexion reported so far, Celgene comes in a bit light. Click to view a price quote on AMGN. Click to research the Drugs industry.    

April 25 (Reuters) - Biotechnology firm Celgene Corp reported a first-quarter profit that edged past analysts' estimates on strong demand for its cancer drugs, Revlimid and Abraxane, and it raised its full-year earnings forecast.

April 25 (Reuters) - Biotechnology firm Celgene Corp reported a first-quarter profit that edged past analysts' estimates on strong demand for its cancer drugs, Revlimid and Abraxane, and it raised its 2013 earnings forecast.

April 25 (Reuters) - Biotechnology firm Celgene Corp reported a first-quarter profit that edged past analysts' estimates on strong demand for its cancer drugs, Revlimid and Abraxane, and it raised its 2013 earnings forecast.

Here's your Cheat Sheet to earnings...

Wall Street is high on Celgene (CELG), expecting it to report earnings that are up 25.3% from a year ago when it reports its first quarter earnings on Thursday, April 25, 2013. The consensus estimate is $1.24 per share, up from earnings of 99 cents p

By Peter Geschek:Apremilast, Celgene's (CELG) experimental drug for psoriasis, in a Phase 3 trial showed good safety profile, but its efficacy was similar to Amgen's (AMGN) Enbrel, and inferior to AbbVie's (ABBV) Humira and Johnson & Johnson's (JNJ)

The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of March.The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Arena Pharmaceuticals (NASDAQ: ARNA), Illumina (NASDAQ:

ByNick Chiu:Celgene (CELG) is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. Celgene's current main products include Revli